SCHEMBL2656333

SCHEMBL2656333

CCN1Cc2nc3c(-c4ccc(OC)c(OC)c4)cccc3c(N)c2C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 5/20 0.44
▸ PIK3CG P48736 1/20 0.40
▸ PDE6C P51160 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ HPGDS O60760 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ HPGD P15428 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ GUSB P08236 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4924170 0.93 TP53 (0.42) PDE5APIK3CGALDH1A1HPGDSGAA
SCHEMBL4917169 0.92 PDE5A (0.42) PDE5APDE6CALDH1A1KDM4EMAPK1
SCHEMBL4915495 0.92 PDE5A (0.41) PDE5APIK3CGPDE6CSIK2
SCHEMBL2661358 0.87 PDE5A (0.40) PDE5APIK3CGALDH1A1KDM4EL3MBTL1
SCHEMBL4923143 0.87 ALDH1A1 (0.39) PIK3CGALDH1A1HPGDSGAAMAPT
SCHEMBL2661396 0.87 PDE5A (0.43) PDE5APDE6CALDH1A1MAPTMEN1
SCHEMBL2661141 0.86 PDE5A (0.40) PDE5APDE6CALDH1A1MAPTKDM4E
SCHEMBL2662436 0.86 GABRG2 (0.49) PDE5A
SCHEMBL4922136 0.86 GABRG2 (0.48) PDE5APDE6CGAANPC1
SCHEMBL2655165 0.85 PDE5A (0.43) PDE5APDE6C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF PDE5A 742/4885PIK3CG 3774/4885PDE6C 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback